Cellectar Biosciences (NASDAQ: CLRB) announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 combined ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE